Efficacy and tolerance of spironolactone in essential hypertension.
about
Drug-induced diabetes mellitusSpironolactone for hypertensionA new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule.Short term effects of spironolactone on blood lipid profile: a 3-month study on a cohort of young women with hirsutismAldosterone synthase inhibition in humansGynecomastia and drugs: a critical evaluation of the literatureHyperaldosteronism in pregnancyAldosterone as a determinant of cardiovascular and renal dysfunctionPrimary Aldosteronism: Changing Definitions and New Concepts of Physiology and Pathophysiology Both Inside and Outside the Kidney.Management of hypertension in primary aldosteronism30 Years of the Mineralocorticoid Receptor: Mineralocorticoid receptor antagonists: 60 years of research and development.Aldosterone-producing adenoma and other surgically correctable forms of primary aldosteronism.Interfering with mineralocorticoid receptor activation: the past, present, and futureLong-term effect of specific treatment of primary aldosteronism on carotid intima-media thicknessMineralocorticoid receptor antagonists as diuretics: Can congestive heart failure learn from liver failure?Diuretic-related side effects: development and treatment.The use of aldosterone receptor blockers in the treatment of hypertension.Gynecomastia and hypertension.Adverse cardiorenal effects of aldosterone: is aldosterone antagonism beneficial?Structure-Based Drug Design of Mineralocorticoid Receptor Antagonists to Explore Oxosteroid Receptor Selectivity.The pharmacological treatment of primary aldosteronism.Does eplerenone have a future in the management of hypertension in Europe?Drospirenone with 17beta-estradiol in the postmenopausal woman with hypertension.Aldosterone as an independent factor in cerebrovascular damage.Review article: eplerenone: an underused medication?Treatment of primary aldosteronism: Where are we now?Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure.Emerging drugs which target the renin-angiotensin-aldosterone system.Primary aldosteronism: from bench to bedside.Mineralocorticoid receptor antagonists: their use and differentiation in Japan.Medical or surgical therapy for primary aldosteronism: post-treatment follow-up as a surrogate measure of comparative outcomes.Diagnosis and management of primary aldosteronism: an updated review.Aldosterone receptor antagonists: current perspectives and therapiesConverging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles.Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure.Pathophysiology, diagnosis, and treatment of mineralocorticoid disorders.Personalizing the diuretic treatment of hypertension: the need for more clinical and research attention.Issues in the Diagnosis and Treatment of Primary Aldosteronism.An update of the blockade of the renin angiotensin aldosterone system in clinical practice.Should All Patients with Resistant Hypertension Receive Spironolactone?
P2860
Q22306015-1CD914C2-2214-4106-BFE1-64AEFC14DF07Q24236324-B37D398E-0EAD-4D25-BA33-D7AD8E122A0DQ24604026-CBF2EA6F-1F48-4ECA-82A8-B081A11059A9Q24653568-7FEC9A92-D6DE-4E25-9347-283CEE576EBBQ27016157-3A8ABDE5-236E-43D1-87B9-40FFFF7A11B6Q28081307-49682D59-AC7A-4CAA-8719-0317D60B1E4FQ28307720-66566856-1101-4F05-8F19-74565F6E8C19Q28344356-A051EED5-A3FF-4265-847C-8CAE0FD5B5DCQ30248429-76890017-A71D-43A8-91D6-E7928564A3F6Q33772765-36807FA4-B1E4-427A-9ABE-9DD7A5D09C42Q33846431-3CC2EF27-2CE1-40A4-8397-750EAAFBD20DQ33930728-D108B5C8-9AF4-4CBB-97D8-8ADBF741CDF5Q34019947-D362DD14-DDC1-4665-8DB2-8BAF06C756DFQ35161719-AAF3FB26-E265-41A9-AA16-71D9BA07EC12Q35272248-9EDF4D07-3F7A-4EE5-97AB-F24347D956E5Q35886396-A54C1F20-EFB6-46B0-959A-B1155A78AD04Q35945724-384DA593-A0AD-4B6B-90F8-6D227782347FQ36110420-AB1DE3A6-A798-4EAC-BB08-6D5B2752FEC2Q36124918-ABED2AC2-2A0A-4EDD-A5E1-2F738290BF4DQ36206559-BB6C6A1A-1B1B-4F34-A7B3-2BCF91576486Q36428495-EC132F32-71FA-42CF-A630-3FD1AED175A3Q36568473-A40A48CA-6E22-4875-925F-0432A4B2FD08Q36761438-5A1E5CD0-6CBF-4909-9087-3A2272849090Q37330163-A5C9FE30-4651-400B-B86E-44328A4B6039Q37793666-A9D19010-FED7-418E-98C6-67532808B922Q37838328-A65335E5-39AD-4FAF-B115-8104036B0013Q37897992-CAFE8F41-2944-4D5A-B721-7D6F033738C5Q37929786-9B31C026-BF6E-4834-BC6A-66FCC9E6EC00Q37951385-6FFAE1F3-15F0-4BC6-82C7-0DF4FDCC4435Q38061551-A34E06D5-DD30-479A-B02F-0613CE8D44F8Q38090512-4925B940-ED27-4492-917A-CE37A75E28E4Q38108818-9881246A-9AD5-4A9C-A6F9-42D583C7C352Q38120241-72E6DF80-F6C1-4FA0-ABEA-FE35F4587F60Q38177168-0DB2ADB6-DDAE-4A7B-A00A-3DE7C229149EQ38182029-7EBB67A0-800E-4504-BBD8-27E6DE91AFECQ38221451-A5D4C314-ACDA-47B5-B870-C31C2CC29B84Q38385760-92910758-B337-4516-B31F-BEE108D5AA03Q38411728-5B496242-E55F-49B4-84B3-0B66F9E40F27Q38590227-08B98E6A-EBCA-45A3-9725-8400EF41AB12Q38992649-106BFED8-5426-4CE0-9639-D4E61721C01F
P2860
Efficacy and tolerance of spironolactone in essential hypertension.
description
1987 nî lūn-bûn
@nan
1987年の論文
@ja
1987年学术文章
@wuu
1987年学术文章
@zh
1987年学术文章
@zh-cn
1987年学术文章
@zh-hans
1987年学术文章
@zh-my
1987年学术文章
@zh-sg
1987年學術文章
@yue
1987年學術文章
@zh-hant
name
Efficacy and tolerance of spironolactone in essential hypertension.
@en
Efficacy and tolerance of spironolactone in essential hypertension.
@nl
type
label
Efficacy and tolerance of spironolactone in essential hypertension.
@en
Efficacy and tolerance of spironolactone in essential hypertension.
@nl
prefLabel
Efficacy and tolerance of spironolactone in essential hypertension.
@en
Efficacy and tolerance of spironolactone in essential hypertension.
@nl
P2093
P1476
Efficacy and tolerance of spironolactone in essential hypertension.
@en
P2093
P304
P356
10.1016/0002-9149(87)91030-7
P407
P577
1987-10-01T00:00:00Z